Top

Published in:

01-07-2012 | Laboratory Investigation

Overactivation of Ras signaling pathway in CD133+ MPNST cells

Authors: Emma Borrego-Diaz, Kaoru Terai, Kristina Lialyte, Amanda L. Wise, Tuba Esfandyari, Fariba Behbod, Victor F. Mautner, Melanie Spyra, Sarah Taylor, Luis F. Parada, Meena Upadhyaya, Faris Farassati

Published in: Journal of Neuro-Oncology | Issue 3/2012

Abstract

Cancer stem cells (CSCs) are believed to be the regenerative pool of cells responsible for repopulating tumors. Gaining knowledge about the signaling characteristics of CSCs is important for understanding the biology of tumors and developing novel anti-cancer therapies. We have identified a subpopulation of cells positive for CD133 (a CSC marker) from human primary malignant peripheral nerve sheath tumor (MPNST) cells which were absent in non-malignant Schwann cells. CD133 was also found to be expressed in human tissue samples and mouse MPNST cells. CD133+ cells were capable of forming spheres in non-adherent/serum-free conditions. The activation levels of Ras and its downstream effectors such as ERK, JNK, PI3K, p38K, and RalA were significantly increased in this population. Moreover, the CD133+ cells showed enhanced invasiveness which was linked to the increased expression of β-Catenin and Snail, two important proteins involved in the epithelial to mesenchymal transition, and Paxilin, a focal adhesion protein. Among other important characteristics of the CD133+ population, endoplasmic reticulum stress marker IRE1α was decreased, implying the potential sensitivity of CD133+ to the accumulation of unfolded proteins. Apoptotic indicators seemed to be unchanged in CD133+ cells when compared to the wild (unsorted) cells. Finally, in order to test the possibility of targeting CD133+ MPNST cells with Ras pathway pharmacological inhibitors, we exposed these cells to an ERK inhibitor. The wild population was more sensitive to inhibition of proliferation by this inhibitor as compared with the CD133+ cells supporting previous studies observing enhanced chemoresistance of these cells.

Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111. doi:10.1038/35102167 PubMedCrossRef

Bignold LP, Coghlan BL, Jersmann HP (2006) Hansemann, Boveri, chromosomes and the gametogenesis-related theories of tumours. Cell Biol Int 30:640–644. doi:10.1016/j.cellbi.2006.04.002 PubMedCrossRef

D’Amour KA, Gage FH (2002) Are somatic stem cells pluripotent or lineage-restricted? Nat Med 8:213–214. doi:10.1038/nm0302-213 PubMedCrossRef

Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.1038/nature03128 PubMedCrossRef

Akhtar K, Bussen W, Scott SP (2009) Cancer stem cells—from initiation to elimination, how far have we reached? (review). Int J Oncol 34:1491–1503PubMed

Trosko JE (2009) Review paper: cancer stem cells and cancer nonstem cells: from adult stem cells or from reprogramming of differentiated somatic cells. Vet Pathol 46:176–193. doi:10.1354/vp.46-2-176 PubMed

Pan Y, Huang X (2008) Epithelial ovarian cancer stem cells—a review. Int J Clin Exp Med 1:260–266PubMed

Sagar J, Chaib B, Sales K, Winslet M, Seifalian A (2007) Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int 7:9. doi:10.1186/1475-2867-7-9 PubMedCrossRef

Spillane JB, Henderson MA (2007) Cancer stem cells: a review. ANZ J Surg 77:464–468. doi:10.1111/j.1445-2197.2007.04096.x PubMedCrossRef

10.

Costa FF, Le Blanc K, Brodin B (2007) Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 25:707–711. doi:10.1634/stemcells.2006-0469 PubMedCrossRef

11.

Mimeault M, Batra SK (2006) Concise review: recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 24:2319–2345. doi:10.1634/stemcells.2006-0066 PubMedCrossRef

12.

Meeker AK, Coffey DS (1997) Telomerase: a promising marker of biological immortality of germ, stem, and cancer cells. A review. Biochemistry 62:1323–1331PubMed

13.

Rudland PS, Ormerod EJ, Paterson FC (1980) Stem cells in rat mammary development and cancer: a review. J R Soc Med 73:437–442PubMed

14.

Polyak K, Hahn WC (2006) Roots and stems: stem cells in cancer. Nat Med 12:296–300. doi:10.1038/nm1379 PubMedCrossRef

15.

Huntly BJ, Gilliland DG (2005) Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 5:311–321. doi:10.1038/nrc1592 PubMedCrossRef

16.

Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11–22PubMedCrossRef

17.

Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG (1994) Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev 8:1019–1029PubMedCrossRef

18.

Goldfinger LE (2008) Choose your own path: specificity in Ras GTPase signaling. Mol Biosyst 4:293–299PubMedCrossRef

19.

Rajalingam K, Schreck R, Rapp UR, Albert S (2007) Ras oncogenes and their downstream targets. Biochim Biophys Acta 1773:1177–1195PubMedCrossRef

20.

Giehl K (2005) Oncogenic Ras in tumour progression and metastasis. Biol Chem 386:193–205PubMedCrossRef

21.

Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC (2004) The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J 23:3061–3071PubMedCrossRef

22.

Harrisingh MC, Lloyd AC (2004) Ras/Raf/ERK signalling and NF1. Cell Cycle 3(10):1255–1258

23.

Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, Shannon K (1996) Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12:144–148PubMedCrossRef

24.

Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW (2001) Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1−/− cells. J Biol Chem 276:7240–7245PubMedCrossRef

25.

Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J (1992) Aberrant regulation of Ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713–715PubMedCrossRef

26.

Lakkis MM, Tennekoon GI (2000) Neurofibromatosis type 1. I. General overview. J Neurosci Res 62:755–763PubMedCrossRef

27.

Upadhyaya M, Spurlock G, Majounie E, Griffiths S, Forrester N, Baser M, Huson SM, Gareth Evans D, Ferner R (2006) The heterogeneous nature of germline mutations in NF1 patients with malignant peripheral serve sheath tumours (MPNSTs). Hum Mutat 27:716PubMedCrossRef

28.

Ferner RE (2007) Neurofibromatosis 1. Eur J Hum Genet 15:131–138PubMedCrossRef

29.

Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, Babovick-Vuksanovic D, Woo RA, Mautner VF, Kluwe L, Clapp DW, De Vries GH, Thomas SL, Kurtz A, Parada LF, Farassati F (2009) Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol 29:3964–3974PubMedCrossRef

30.

Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, Farmer GE, Freiman RN, Lee JK, Li FP (1990) Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA 87:5435–5439PubMedCrossRef

31.

Legius E, Dierick H, Wu R, Hall BK, Marynen P, Cassiman JJ, Glover TW (1994) TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 10:250–255PubMedCrossRef

32.

Rey JA, Pestana A, Bello MJ (1992) Cytogenetics and molecular genetics of nervous system tumors. Oncol Res 4:321–331PubMed

33.

Farassati F, Yang AD, Lee PW (2001) Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3:745–750PubMedCrossRef

34.

Corbeil D, Fargeas CA, Huttner WB (2001) Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein. Biochem Biophys Res Commun 285:939–944. doi:10.1006/bbrc.2001.5271 PubMedCrossRef

35.

Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2:82–91PubMedCrossRef

36.

Mehra N, Penning M, Maas J, Beerepoot LV, van Daal N, van Gils CH, Giles RH, Voest EE (2006) Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 12:4859–4866. doi:10.1158/1078-0432.CCR-06-0422 PubMedCrossRef

37.

Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90:5013–5021PubMed

38.

Salmaggi A, Boiardi A, Gelati M, Russo A, Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La Porta C, Alessandri G, Marras C, Croci D, De Rossi M (2006) Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54:850–860. doi:10.1002/glia.20414 PubMedCrossRef

39.

Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43:935–946. doi:10.1016/j.ejca.2007.01.017 PubMedCrossRef

40.

O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106–110. doi:10.1038/nature05372 PubMedCrossRef

41.

Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946–10951. doi:10.1158/0008-5472.CAN-05-2018 PubMedCrossRef

42.

Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ (2007) Tumour-initiating cells vs. cancer ‘stem’ cells and CD133: What’s in the name? Biochem Biophys Res Commun 355:855–859. doi:10.1016/j.bbrc.2007.01.159 PubMedCrossRef

43.

Hambardzumyan D, Squatrito M, Holland EC (2006) Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10:454–456. doi:10.1016/j.ccr.2006.11.008 PubMedCrossRef

44.

Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A (2007) HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17:165–172. doi:10.1016/j.cub.2006.11.033 PubMedCrossRef

45.

Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, Frank MH (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65:4320–4333. doi:10.1158/0008-5472.CAN-04-3327 PubMedCrossRef

46.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760. doi:10.1038/nature05236 PubMedCrossRef

47.

Mashour GA, Drissel SN, Frahm S, Farassati F, Martuza RL, Mautner VF, Kindler-Rohrborn A, Kurtz A (2005) Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids. Oncogene 24:2367–2374PubMedCrossRef

48.

Thomas SL, Deadwyler GD, Tang J, Stubbs EB Jr, Muir D, Hiatt KK, Clapp DW, De Vries GH (2006) Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells. Biochem Biophys Res Commun 348:971–980. doi:S0006-291X(06)01704-910.1016/j.bbrc.2006.07.159 PubMedCrossRef

49.

Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF (1999) Mouse tumor model for neurofibromatosis type 1. Science 286:2176–2179PubMedCrossRef

50.

Bergeron JJ, Brenner MB, Thomas DY, Williams DB (1994) Calnexin: a membrane-bound chaperone of the endoplasmic reticulum. Trends Biochem Sci 19:124–128PubMedCrossRef

51.

Kohno K, Normington K, Sambrook J, Gething MJ, Mori K (1993) The promoter region of the yeast KAR2 (BiP) gene contains a regulatory domain that responds to the presence of unfolded proteins in the endoplasmic reticulum. Mol Cell Biol 13:877–890PubMed

52.

Ellgaard L, Ruddock LW (2005) The human protein disulphide isomerase family: substrate interactions and functional properties. EMBO Rep 6:28–32. doi:10.1038/sj.embor.7400311 PubMedCrossRef

53.

Cabibbo A, Pagani M, Fabbri M, Rocchi M, Farmery MR, Bulleid NJ, Sitia R (2000) ERO1-L, a human protein that favors disulfide bond formation in the endoplasmic reticulum. J Biol Chem 275:4827–4833PubMedCrossRef

54.

Cox JS, Shamu CE, Walter P (1993) Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 73:1197–1206PubMedCrossRef

55.

Harding HP, Zhang Y, Ron D (1999) Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397:271–274. doi:10.1038/16729 PubMedCrossRef

56.

Shi Y, Vattem KM, Sood R, An J, Liang J, Stramm L, Wek RC (1998) Identification and characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol Cell Biol 18:7499–7509PubMed

57.

Hancock CN, Macias A, Lee EK, Yu SY, Mackerell AD Jr, Shapiro P (2005) Identification of novel extracellular signal-regulated kinase docking domain inhibitors. J Med Chem 48:4586–4595. doi:10.1021/jm0501174 PubMedCrossRef

58.

Spyra M, Kluwe L, Hagel C, Nguyen R, Panse J, Kurtz A, Mautner VF, Rabkin SD, Demestre M (2011) Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors. PLoS ONE 6:e21099. doi:10.1371/journal.pone.0021099 PubMedCrossRef

59.

Farassati F, Pan W, Yamoutpour F, Henke S, Piedra M, Frahm S, Al-Tawil S, Mangrum WI, Parada LF, Rabkin SD, Martuza RL, Kurtz A (2008) Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am J Pathol 173:1861–1872PubMedCrossRef

60.

Norman KL, Farassati F, Lee PW (2001) Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev 12:271–282PubMedCrossRef

61.

Pan W, Bodempudi V, Esfandyari T, Farassati F (2009) Utilizing Ras signaling pathway to direct selective replication of herpes simplex virus-1. PLoS ONE 4:e6514PubMedCrossRef

62.

Tabu K, Kimura T, Sasai K, Wang L, Bizen N, Nishihara H, Taga T, Tanaka S (2010) Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer 9:39. doi:10.1186/1476-4598-9-39 PubMedCrossRef

63.

Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2:76–83. doi:10.1038/35000025 PubMedCrossRef

64.

Kato N, Shimmura S, Kawakita T, Miyashita H, Ogawa Y, Yoshida S, Higa K, Okano H, Tsubota K (2007) Beta-catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium. Invest Ophthalmol Vis Sci 48:1511–1517. doi:10.1167/iovs.06-1060 PubMedCrossRef

65.

Zheng G, Lyons JG, Tan TK, Wang Y, Hsu TT, Min D, Succar L, Rangan GK, Hu M, Henderson BR, Alexander SI, Harris DC (2009) Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol 175:580–591. doi:10.2353/ajpath.2009.080983 PubMedCrossRef

66.

McGuire JK, Li Q, Parks WC (2003) Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 162:1831–1843PubMedCrossRef

67.

Monteiro J, Fodde R (2010) Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 46:1198–1203. doi:10.1016/j.ejca.2010.02.030 PubMedCrossRef

68.

Maheswaran S, Haber DA (2010) Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev 20:96–99. doi:10.1016/j.gde.2009.12.002 PubMedCrossRef

69.

Wang G, Yang ZQ, Zhang K (2010) Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Transl Res 2:65–74PubMed

70.

Schleicher SM, Moretti L, Varki V, Lu B (2010) Progress in the unraveling of the endoplasmic reticulum stress/autophagy pathway and cancer: implications for future therapeutic approaches. Drug Resist Updates 13:79–86. doi:10.1016/j.drup.2010.04.002 CrossRef

71.

Lisbona F, Hetz C (2009) Turning off the unfolded protein response: an interplay between the apoptosis machinery and ER stress signaling. Cell Cycle 8:1643–1644PubMedCrossRef

72.

Lisbona F, Rojas-Rivera D, Thielen P, Zamorano S, Todd D, Martinon F, Glavic A, Kress C, Lin JH, Walter P, Reed JC, Glimcher LH, Hetz C (2009) BAX inhibitor-1 is a negative regulator of the ER stress sensor IRE1alpha. Mol Cell 33:679–691. doi:10.1016/j.molcel.2009.02.017 PubMedCrossRef

Title: Overactivation of Ras signaling pathway in CD133+ MPNST cells
Authors: Emma Borrego-Diaz
Kaoru Terai
Kristina Lialyte
Amanda L. Wise
Tuba Esfandyari
Fariba Behbod
Victor F. Mautner
Melanie Spyra
Sarah Taylor
Luis F. Parada
Meena Upadhyaya
Faris Farassati
Publication date: 01-07-2012
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 3/2012
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-012-0852-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Overactivation of Ras signaling pathway in CD133+ MPNST cells

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Erratum to: Development of a novel animal model to differentiate radiation necrosis from tumor recurrence

Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy

Stereotactic radiosurgery for intracranial chondrosarcoma

Identifying the palliative care needs of patients living with cerebral tumors and metastases: a retrospective analysis

Stereotactic radiosurgery for patients with recurrent intracranial ependymomas

Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study